Plus Therapeutics : January Investor Presentation

Corporate Presentation

January 2021

Forward-Looking Statements

This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Any statement in this document that is not a historical fact is a "forward-looking statements" within the meaning of Section 27A of the Securities Act and Section 21E of the Securities Exchange Act and are usually identified by the use of words such as "anticipates," "believes," "estimates," "expects," "intends," "may," "plans," "projects," "seeks," "should," "will," and variations of such words or similar expressions. We intend these forward-looking statements to be covered by the safe harbor provisions for forward-looking statements contained in Section 27A of the Securities Act and Section 21E of the Securities Exchange Act of 1934, as amended, and are making this statement for purposes of complying with those safe harbor provisions. These forward- looking statements reflect our current views about our plans, intentions, expectations, strategies and prospects, which are based on the information currently available to us and on assumptions we have made. Although we believe that our plans, intentions, expectations, strategies and prospects as reflected in or suggested by those forward-looking statements are reasonable, we can give no assurance that the plans, intentions, expectations or strategies will be attained or achieved. Furthermore, actual results may differ materially from those described in the forward-looking statements and will be affected by a variety of risks and factors that are beyond our control.

Risks and uncertainties for Plus include, but are not limited to: an inability or delay in obtaining required regulatory approvals for product candidates, which may result in unexpected cost expenditures; risks inherent in drug development in general; uncertainties in obtaining successful clinical results for product candidates and unexpected costs that may result therefrom; failure to realize any value of certain product candidates developed and being developed in light of inherent risks and difficulties involved in successfully bringing product candidates to market; inability to develop new product candidates and support existing products; the approval by the FDA and any other similar foreign regulatory authorities of other competing or superior products brought to market; risks resulting from unforeseen side effects; risk that the market for the combined company's products may not be as large as expected; inability to obtain, maintain and enforce patents and other intellectual property rights or the unexpected costs associated with such enforcement or litigation; inability to obtain and maintain commercial manufacturing arrangements with third-party manufacturers or establish commercial scale manufacturing capabilities; loss of or diminished demand from one or more key customers or distributors; unexpected cost increases and pricing pressures; economic recession and its negative impact on customers, vendors or suppliers; uncertainties of cash flows, expenses and inability to meet working capital needs; and other risks and uncertainties detailed in the risk factors section of Plus' Form 10-K and Forms 10- Q filed with the SEC, as well as other filings Plus makes with the SEC from time-to-time. Many of these factors that will determine actual results are beyond Plus' ability to control or predict. Plus disclaims any obligation to update information contained in these forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.

2

We believe in the critical importance and urgency in developing and delivering complex, innovative treatments for patients battling rare CNS cancers.

3

PLUS Therapeutics: A CNS Oncology Company

✚ Significant unmet medical needs

FACTS ABOUT BRAIN TUMORS

+	5-year survival - 36%
+	Few approved treatments

An estimated 700,000+ PEOPLE in the U.S. are living with a primary

brain or central nervous system (CNS) tumor diagnosis:

210,000 WITH MALIGNANT TUMORS

490,000 WITH NON-MALIGNANT TUMORS

PRIMARY BRAIN

TUMOR TYPES

✚ Rare diseases
+	FDA ODD eligible
+	Sizeable aggregate population
✚ Pathophysiologic overlap

APPROXIMATELY

6-28%

OF ALL OTHER CANCERS LATER DEVELOP A CNS METASTASES

This accounts for 70,000 to 170,000 new patients diagnosed with CNS metastases each year.

IN 2020, NEW PRIMARY BRAIN TUMOR DIAGNOSES INCLUDED

70%	30%
NON-MALIGNANT	MALIGNANT
TUMORS	TUMORS
(58,860 Cases)	(24,970 CASES)

Meningioma (38%)

Pituitary (17%)

Glioblastoma (15%)

Other Non-Glioma (11%)

Other Glioma (11%)

Nerve Sheath (9%)

Sources: CBTRUS Statistical Report, NBTS

4